The following video is an interview with Professor Thomas Powles from Barts Cancer Centre in London, where he is Professor of Genitourinary Oncology. During the interview, Professor Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium. The data from KETNOTE-426 potentially redefines the standard of care in […]
The Food and Drug Administration (FDA) in the United States has approved the pembrolizumab (Keytruda) plus axitinib (Inlyta) combination for first-line treatment of advanced renal cell carcinoma (RCC). The approval comes two months earlier than expected and is based on the results from the open-label KEYNOTE-426 study involving 861 patients. In this study, median progression-free […]
As the hunt for a reliable biomarker for renal cell carcinoma (RCC) continues, two further studies this month reveal potential candidates. The first study, published in Targeted Oncology, describes serum (blood) α1-globulin as an independent predictor (prognostic factor) of overall survival and progression-free survival in metastatic RCC, and is correlated with a high amount of […]
The results of a recent phase 2 study to evaluate the safety and efficacy of anlotinib for the first-line treatment of metastatic renal cell carcinoma (RCC) were published in The Oncologist this month. Anlotinib was developed in China, and is a new tyrosine kinase inhibitor inhibiting multiple kinases involved in the growth of new blood […]
A recent study, published in the journal Advances in Medicine and Medical Research, suggests that the presence of hand-foot syndrome in patients with metastatic renal cell carcinoma (RCC) after the first cycle of treatment with sunitinib predicts longer progression-free survival. Median progression-free survival was 9.8 months in those patients who did not experience hand-foot syndrome […]
New 30-month survival data from the CheckMate 214 study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Additional 30-month follow-up data from the phase 3 CheckMate 214 trial confirms the survival benefit of the nivolumab plus ipilimumab combination over sunitinib as a first-line treatment for patients […]
The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Toni Choueiri from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA, presented updated results from the JAVELIN Renal 101 clinical trial. The results showed that treatment with a […]
The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Professor Thomas Powles from the Barts Cancer Institute in London presented the results from KEYNOTE-426, a global, open-label, phase 3 study to assess the efficacy and safety of pembrolizumab plus […]
Further survival data has been released from the phase 3 CheckMate-214 study, showing that treatment with a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to demonstrate long-term survival benefits in patients with previously untreated advanced/metastatic renal cell carcinoma (RCC) after 30 months follow-up. Patients with intermediate- and poor-risk untreated RCC treated with the nivolumab/ipilimumab […]
Using gene profiling, a recent study published in Cancer Discovery has identified four distinct molecular subgroups associated with response to treatment with sunitinib or pazopanib and survival. The findings demonstrate the effects of the presence of immune cells and angiogenesis on the effectiveness of sunitinib and pazopanib against the cancer, and are important for individualised decision-making. […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
